Americans once associated bootlegging with bathtub gin, counterfeit liquor, and criminal syndicates exploiting Prohibition-era loopholes. Eliot Ness built his reputation chasing criminal networks that profited by selling dangerous, unregulated alcohol to consumers who had no idea what was in the bottle. Nearly a century later, America faces a biotech version of the same racket — only today’s bootleggers wear wellness-brand hoodies, operate through anonymous peptide websites, telehealth-style storefronts, influencer-driven social media channels, and online marketplaces selling products labeled “retatrutide” before FDA has even approved the drug.
The technology changed. The contempt for regulation has not.
The packaging may look sleek. The marketing language may sound “science-forward.” But the business model is pure Prohibition: exploit consumer demand, evade oversight, and profit from products nobody can independently verify.
As public excitement around retatrutide intensifies — fueled by speculation that it could become the next blockbuster obesity therapy after GLP-1 drugs — a growing online gray market is behaving as though FDA approval is already a foregone conclusion. It isn’t.
Retatrutide remains an investigational drug under FDA review. It is not approved for patient use.
That inconvenient truth hasn’t stopped a rapidly expanding ecosystem of peptide vendors, wellness clinics, med spas, telehealth-style operators, and social media profiteers from marketing products labeled “Reta,” “GLP-3,” or “retatrutide” as though they are simply the next generation of Ozempic-style medicines. Some sellers even imply these products are equivalent — or superior — to FDA-approved therapies already on the market.
Let’s call this what it is: not innovation, not “expanded access,” and certainly not patient empowerment. It is the commercial trafficking of an unapproved investigational drug.
And unlike compounded knockoffs of FDA-approved GLP-1 medicines — themselves the subject of increasing FDA scrutiny — no FDA-approved version of retatrutide even exists. There is no legal commercial marketplace to imitate. No authorized manufacturing pathway. No legitimate retail supply chain. That’s a distinction with a difference.
Over the past year, FDA has finally begun reasserting some badly needed regulatory muscle over the runaway compounded GLP-1 marketplace. Warning letters, litigation, enforcement actions, and tightening policy signals reflect growing recognition that “temporary shortage” cannot become a permanent business model for parallel pharmaceutical commerce.
But retatrutide represents something even more dangerous: the normalization of a pre-approval black market for investigational medicines.
This is no longer about copycat versions of approved drugs. It is about commercializing molecules that have not yet completed FDA review — effectively transforming the internet into an unregulated phase-four clinical trial without physicians, oversight, data integrity, or accountability.
And if regulators move too slowly, the public will begin treating these illegal markets as normal long before they understand the risks.
Consumers ordering “retatrutide” online have no meaningful way to know what they are injecting. No validated manufacturing standards. No assurance of sterility, potency, purity, dosing consistency, or even ingredient authenticity. No reliable adverse-event reporting. No accountability when contamination or injury occurs.
Some sellers attempt to hide behind the absurd legal fiction of “research use only” disclaimers while openly marketing products through consumer-facing wellness platforms. FDA has already made clear in recent peptide enforcement actions that slapping “not for human consumption” on a website does not magically legalize the commercial sale of unapproved drugs intended for human use, but a disclaimer is not a force field nor is it a cone of silence.
But the larger issue isn’t merely counterfeit products or consumer fraud. It is the erosion of the entire scientific and regulatory framework designed to determine whether medicines are safe and effective before mass commercialization begins.
Clinical trials exist for a reason. Legitimate drug development includes physician supervision, controlled dosing, adverse-event monitoring, manufacturing oversight, and rigorous scientific accountability. Buying mystery peptides from an online storefront offers none of those safeguards.
Allowing investigational obesity drugs to become internet lifestyle products before FDA review is complete doesn’t democratize medicine. It degrades medicine.
Science cannot function when influencer marketing outruns regulatory science. Clinical development cannot become a popularity contest dictated by TikTok algorithms, Reddit forums, and black-market demand curves.
FDA should not wait for this market to metastasize before acting more aggressively.
FDA should not wait for this market to metastasize before acting more aggressively. Eliot Ness understood that once bootlegging networks became culturally normalized, enforcement became exponentially harder. The same principle applies here. Every month regulators hesitate, these illegal pharmaceutical gray markets become more sophisticated, more profitable, and more entrenched.
Federal regulators — including FDA, FTC, Customs and Border Protection, and state Attorneys General — should coordinate enforcement now against online peptide sellers, wellness clinics, med spas, telehealth-style platforms, and payment processors facilitating the unauthorized sale of “retatrutide” products outside legitimate research settings. The longer regulators hesitate, the harder this parallel marketplace becomes to unwind.
Depression-era bank robber Willie Sutton was famously asked why he robbed banks. His answer: “Because that’s where the money is.” Today’s digital bootleggers are chasing obesity drugs for the same reason. Not because the science is settled. Not because FDA approval exists. Not because patient protections are in place. But because demand is enormous, regulation is lagging, and the money is flowing.
The bottom line is straightforward: investigational medicines still under FDA review should not be sold to consumers as commercial wellness products. That is not scientific progress.
It is digital-age bootlegging.
Peter J. Pitts, a former FDA Associate Commissioner, is President of the Center for Medicine in the Public Interest.
